Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.

Cancer SciJul 6, 2026 (epub)
Clinical ResearchOncology (Medical)Medical GeneticsOpen access

Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase II trial evaluated the efficacy and safety of nivolumab in patients with advanced solid tumors based on comprehensive genomic profiling (CGP) results. Among 56 patients treated, the overall response rate (ORR) was 16.0% and the disease control rate (DCR) was 40.0%. The study highlights the limited efficacy of CGP-guided nivolumab treatment.

Key findings

  • The overall response rate (ORR) was 16.0% among patients with measurable disease.
  • The disease control rate (DCR) was 40.0% in the treated cohort.
  • Median progression-free survival (PFS) was 2.7 months.
  • Median overall survival (OS) was 7.2 months.

Why it matters

Understanding the efficacy of nivolumab based on genomic profiling can inform treatment decisions for patients with advanced solid tumors, although the limited response rates suggest a need for further research.

Source

PubMed · PMID 42410894Free full text on PubMed Central

Published in Cancer Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.